ReP USP - Resultado da busca

Artigo de periodico
Evolocumab treatment in pediatric patients with homozygous familial hypercholesterolemia: pooled data from three open-label studies (2024)
Raal, Frederick J.; Hegele, Robert A.; Ruzza, Andrea; Lopez, J. Antonio G.; Bhatia, Ajay K.; Wu, Johnny; Wang, Huei; Gaudet, Daniel; Wiegman, Albert; Wang, Jian; Santos Filho, Raul Dias dos
Source: Arteriosclerosis thrombosis and vascular biology. Unidade: FM
Subjects: DOENÇAS CARDIOVASCULARES, FATORES DE RISCO, HIPERCOLESTEROLEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RAAL, Frederick J. et al. Evolocumab treatment in pediatric patients with homozygous familial hypercholesterolemia: pooled data from three open-label studies. Arteriosclerosis thrombosis and vascular biology, v. 44, n. 5, p. 1156-1164, 2024Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/76876. Acesso em: 05 maio 2026.
APA
Raal, F. J., Hegele, R. A., Ruzza, A., Lopez, J. A. G., Bhatia, A. K., Wu, J., et al. (2024). Evolocumab treatment in pediatric patients with homozygous familial hypercholesterolemia: pooled data from three open-label studies. Arteriosclerosis thrombosis and vascular biology, 44( 5), 1156-1164. doi:10.1161/ATVBAHA.123.320268
NLM
Raal FJ, Hegele RA, Ruzza A, Lopez JAG, Bhatia AK, Wu J, Wang H, Gaudet D, Wiegman A, Wang J, Santos Filho RD dos. Evolocumab treatment in pediatric patients with homozygous familial hypercholesterolemia: pooled data from three open-label studies [Internet]. Arteriosclerosis thrombosis and vascular biology. 2024 ; 44( 5): 1156-1164.[citado 2026 maio 05 ] Available from: https://observatorio.fm.usp.br/handle/OPI/76876
Vancouver
Raal FJ, Hegele RA, Ruzza A, Lopez JAG, Bhatia AK, Wu J, Wang H, Gaudet D, Wiegman A, Wang J, Santos Filho RD dos. Evolocumab treatment in pediatric patients with homozygous familial hypercholesterolemia: pooled data from three open-label studies [Internet]. Arteriosclerosis thrombosis and vascular biology. 2024 ; 44( 5): 1156-1164.[citado 2026 maio 05 ] Available from: https://observatorio.fm.usp.br/handle/OPI/76876
Artigo de periodico
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance (2023)
Cuchel, Marina; Raal, Frederick J; Hegele, Robert A; Al-Rasadi, Khalid ; Arca, Marcello; Averna, Maurizio; Bruckert, Eric; Freiberger, Tomas; Gaudet, Daniel; Harada-Shiba, Mariko; Santos Filho, Raul Dias dos
Source: European heart journal. Unidade: FM
Subjects: HIPERCOLESTEROLEMIA, MULHERES, CONSENSO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CUCHEL, Marina et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. European heart journal, v. 44, n. 25, p. 2277-2291, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/54630. Acesso em: 05 maio 2026.
APA
Cuchel, M., Raal, F. J., Hegele, R. A., Al-Rasadi, K., Arca, M., Averna, M., et al. (2023). 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. European heart journal, 44( 25), 2277-2291. doi:10.1093/eurheartj/ehad197
NLM
Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, Bruckert E, Freiberger T, Gaudet D, Harada-Shiba M, Santos Filho RD dos. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance [Internet]. European heart journal. 2023 ; 44( 25): 2277-2291.[citado 2026 maio 05 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54630
Vancouver
Cuchel M, Raal FJ, Hegele RA, Al-Rasadi K, Arca M, Averna M, Bruckert E, Freiberger T, Gaudet D, Harada-Shiba M, Santos Filho RD dos. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance [Internet]. European heart journal. 2023 ; 44( 25): 2277-2291.[citado 2026 maio 05 ] Available from: https://observatorio.fm.usp.br/handle/OPI/54630
Artigo de periodico
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial (2021)
Tardif, Jean-Claude; Bouabdallaoui, Nadia; L'allier, Philippe L; Gaudet, Daniel; Shah, Binita; Pillinger, Michael H; Lopez-Sendon, Jose; Luz, Protásio Lemos da ; Verret, Lucie; Audet, Sylvia
Source: Lancet respiratory medicine. Unidade: FM
Subjects: COVID-19, INFLAMAÇÃO, FÁRMACOS SINTÉTICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TARDIF, Jean-Claude et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet respiratory medicine, v. 9, n. 8, p. 924-932, 2021Tradução . . Disponível em: https://doi.org/10.1016/S2213-2600(21)00222-8. Acesso em: 05 maio 2026.
APA
Tardif, J. -C., Bouabdallaoui, N., L'allier, P. L., Gaudet, D., Shah, B., Pillinger, M. H., et al. (2021). Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet respiratory medicine, 9( 8), 924-932. doi:10.1016/S2213-2600(21)00222-8
NLM
Tardif J-C, Bouabdallaoui N, L'allier PL, Gaudet D, Shah B, Pillinger MH, Lopez-Sendon J, Luz PL da, Verret L, Audet S. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial [Internet]. Lancet respiratory medicine. 2021 ; 9( 8): 924-932.[citado 2026 maio 05 ] Available from: https://doi.org/10.1016/S2213-2600(21)00222-8
Vancouver
Tardif J-C, Bouabdallaoui N, L'allier PL, Gaudet D, Shah B, Pillinger MH, Lopez-Sendon J, Luz PL da, Verret L, Audet S. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial [Internet]. Lancet respiratory medicine. 2021 ; 9( 8): 924-932.[citado 2026 maio 05 ] Available from: https://doi.org/10.1016/S2213-2600(21)00222-8
Artigo de periodico
No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels (2020)
Zheng, Kang H; Kaiser, Yannick; Olden, Casper C. van; Santos Filho, Raul Dias dos ; Dasseux, Jean-Louis; Genest, Jacques; Gaudet, Daniel; Westerink, Jan; Verberne, Hein J
Source: Atherosclerosis. Unidade: FM
Subjects: APOLIPOPROTEÍNAS, COLESTEROL, LIPOPROTEÍNAS HDL, MEIA IDADE, FOSFOLIPÍDEOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ZHENG, Kang H et al. No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. Atherosclerosis, v. 311, p. 13-19, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.atherosclerosis.2020.08.004. Acesso em: 05 maio 2026.
APA
Zheng, K. H., Kaiser, Y., Olden, C. C. van, Santos Filho, R. D. dos, Dasseux, J. -L., Genest, J., et al. (2020). No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels. Atherosclerosis, 311, 13-19. doi:10.1016/j.atherosclerosis.2020.08.004
NLM
Zheng KH, Kaiser Y, Olden CC van, Santos Filho RD dos, Dasseux J-L, Genest J, Gaudet D, Westerink J, Verberne HJ. No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels [Internet]. Atherosclerosis. 2020 ; 311 13-19.[citado 2026 maio 05 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2020.08.004
Vancouver
Zheng KH, Kaiser Y, Olden CC van, Santos Filho RD dos, Dasseux J-L, Genest J, Gaudet D, Westerink J, Verberne HJ. No benefit of HDL mimetic CER-001 on carotid atherosclerosis in patients with genetically determined very low HDL levels [Internet]. Atherosclerosis. 2020 ; 311 13-19.[citado 2026 maio 05 ] Available from: https://doi.org/10.1016/j.atherosclerosis.2020.08.004

USP Schools

ReP

Filtros

Authors

Subjects

Funding Agencies

Non normalized affiliation

Countries of institutions of collaboration